Management of diabetic macular oedema in France from 2012 to 2018: The nationwide LANDSCAPE study

Management of Neovascular Age-Related Macular Degeneration Treatment in France from 2008–2018: The Nationwide LANDSCAPE Study

(2023) Catherine P. Creuzot Garcher et al.   Ophthalmology and Therapy

TITLE

(2022) Pierre-Henry Gabrielle et al.   RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES

Two-year outcomes of the APOLLON observational study of intravitreal aflibercept monotherapy in France in patients with diabetic macular edema

(2022) Jean-François Korobelnik et al.   Scientific Reports

Epidemiology of Treated Diabetes Ocular Complications in France 2008–2018—The LANDSCAPE French Nationwide Study

(2022) Catherine Creuzot-Garcher et al.   Pharmaceutics

Intravitreal anti‐VEGF use in France: a cross‐sectional and longitudinal Nationwide observational study

(2021) Sophie Billioti de Gage et al.   ACTA OPHTHALMOLOGICA

ETOILE: Real-World Evidence of 24 Months of Ranibizumab 0.5 mg in Patients with Visual Impairment Due to Diabetic Macular Edema

(2021) Laurent Kodjikian et al.   Clinical Ophthalmology

Real-world outcomes following 12 months of intravitreal aflibercept monotherapy in patients with diabetic macular edema in France: results from the APOLLON study

(2020) Jean-François Korobelnik et al.   GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY

Expectations and fears of patients with diabetes and macular edema treated by intravitreal injections

(2020) Franck Fajnkuchen et al.   ACTA DIABETOLOGICA

Changes in real‐world treatment patterns for diabetic macular oedema from 2009‐2019 and five‐year outcomes: Data from the Fight Retinal Blindness! Registry

(2020) Anne C. Biechl et al.   CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY

Effectiveness and safety of ranibizumab 0.5 mg in treatment-naïve patients with diabetic macular edema: Results from the real-world global LUMINOUS study

(2020) Paul Mitchell et al.   PLoS One

Real-world outcomes after 36 months treatment with ranibizumab 0.5 mg in patients with visual impairment due to diabetic macular edema (BOREAL-DME)

(2020) Pascale Massin et al.   OPHTHALMIC RESEARCH

Analysis of Patient-Reported Barriers to Diabetic Retinopathy Follow-Up

(2019) Amanda J. Lu et al.   Ophthalmic Surgery Lasers & Imaging Retina

Real-World Outcomes with Ranibizumab 0.5 mg in Patients with Visual Impairment due to Diabetic Macular Edema: 12-Month Results from the 36-Month BOREAL-DME Study

(2019) Pascale Massin et al.   OPHTHALMIC RESEARCH

Real-world outcomes of non-responding diabetic macular edema treated with continued anti-VEGF therapy versus early switch to dexamethasone implant: 2-year results

(2019) Catharina Busch et al.   ACTA DIABETOLOGICA

Treatment Patterns for Diabetic Macular Edema: An Intelligent Research in Sight (IRIS®) Registry Analysis

(2019) Ronald A. Cantrell et al.   OPHTHALMOLOGY

Ranibizumab or Aflibercept for Diabetic Macular Edema: Comparison of One-Year Outcomes from the Fight Retinal Blindness! Registry

(2019) Sanjeeb Bhandari et al.   OPHTHALMOLOGY

A noninterventional study to monitor patients with diabetic macular oedema starting treatment with ranibizumab (POLARIS)

(2018) Jana Stefanickova et al.   ACTA OPHTHALMOLOGICA

Ranibizumab for the Treatment of Diabetic Macular Oedema in the Real-World Clinical Setting in Portugal: A Multicentre Study

(2018) Cláudia Farinha et al.   OPHTHALMOLOGICA

LONG-TIME OUTCOME IN PATIENTS TREATED WITH RANIBIZUMAB FOR DIABETIC MACULAR EDEMA

(2018) David Epstein et al.   RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES

Treatment Efficacy and Compliance in Patients with Diabetic Macular Edema Treated with Ranibizumab in a Real-Life Setting

(2018) Anne-Laurence Best et al.   Journal of Ophthalmology

Anti–Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema in a Real-World Clinical Setting

(2018) Emilia Maggio et al.   AMERICAN JOURNAL OF OPHTHALMOLOGY

French administrative health care database (SNDS): The value of its enrichment

(2018) Lucie-Marie Scailteux et al.   THERAPIE

French Medical-Administrative Database for Epidemiology and Safety in Ophthalmology (EPISAFE): The EPISAFE Collaboration Program in Cataract Surgery

(2017) Vincent Daien et al.   OPHTHALMIC RESEARCH

Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA)

(2017) Ursula Schmidt-Erfurth et al.   OPHTHALMOLOGICA

REAL-LIFE STUDY IN DIABETIC MACULAR EDEMA TREATED WITH DEXAMETHASONE IMPLANT

(2017) Ariane Malclès et al.   RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES

Value of a national administrative database to guide public decisions: From the système national d’information interrégimes de l’Assurance Maladie (SNIIRAM) to the système national des données de santé (SNDS) in France

(2017) P. Tuppin et al.   REVUE D EPIDEMIOLOGIE ET DE SANTE PUBLIQUE

The United Kingdom Diabetic Retinopathy Electronic Medical Record Users Group, Report 1: baseline characteristics and visual acuity outcomes in eyes treated with intravitreal injections of ranibizumab for diabetic macular oedema

(2016) Catherine Egan et al.   BRITISH JOURNAL OF OPHTHALMOLOGY

Outcomes after a 1-Year Treatment with Ranibizumab for Diabetic Macular Edema in a Clinical Setting

(2016) Linda Hrarat et al.   OPHTHALMOLOGICA

Treatment Patterns of Anti-Vascular Endothelial Growth Factor and Laser Therapy Among Patients with Diabetic Macular Edema

(2015) Shan Jiang et al.   Journal of Managed Care & Specialty Pharmacy

The 25-Year Incidence of Visual Impairment in Type 1 Diabetes Mellitus

(2009) Ronald Klein et al.   OPHTHALMOLOGY